One of many barely plausible statistics of this 12 months’s Ash convention is that its sessions comprise data on 29 different projects targeting the BCMA antigen. However what about novel targets that may both be much less crowded competitively or whose focusing on may deal with a number of myeloma that has relapsed after BCMA remedy?
Saturday noticed promising medical outcomes unveiled from two tasks which have largely flown beneath the radar, Johnson & Johnson/Genmab’s talquetamab and Roche’s cevostamab. These impressed with their information and aggressive positions alike: the latter’s pharmacology is exclusive, whereas the previous has only one potential rival with the identical mechanism.
Talquetamab is a bispecific towards the GPRC5D antigen, a plasma cell goal that triggered a ripple of curiosity at Ash two years in the past, courtesy of Memorial Sloan Kettering’s Automobile-T asset MCARH109. GPRC5D expression was mentioned to be unbiased of BCMA, and MCARH109 has lately entered part I.
This 12 months talquetamab backed up the promise of GPRC5D with information from a dose-escalation trial that has now handled 157 sufferers who had obtained a median six prior therapies.
Dr Ajai Chari of Mount Sinai Medical Middle dismissed the bottom doses as inactive, however centered on 50 evaluable topics given over 20µg/kg, in whom the response fee was 66%. He zeroed in on 13 sufferers who had obtained 405µg/kg subcutaneously, which has been set because the part II dose, and the place the ORR was 69%.
Dr Chari had examined IV and SC administration, and whereas each triggered cytokine launch syndrome solely IV was related to this toxicity above grade 2; an 800µg/kg dose triggered grade three rash and won’t be taken ahead. Throughout all sufferers 27 had progressed on anti-BCMA remedy, however Dr Chari mentioned numbers have been too small to touch upon their remission charges.